AbbVie gets FDA approval for Hepatitis C combination therapy

AbbVie gets FDA approval for Hepatitis C combination therapy Daklinza plus sofosbuvir resulted in 90% SVR12 in treatment-naive and 86% in treatment-experienced chronic HCV genotype 3 patients. Most people infected with HCV have no symptoms of the disease until liver … Continue reading